Deoxycholic Acid Test

If you have chronic kidney disease, a fatty liver, or a family history of either, there is a molecule made by your gut bacteria that may be quietly raising your risk of dying from heart disease or progressing to dialysis. It does not show up on a basic metabolic panel, a lipid panel, or a standard liver test.

DCA (deoxycholic acid) is one of the clearest windows we have into how your gut microbes, your liver, and your metabolic health are interacting. Elevated levels have been tied to vascular calcification, lower bone density, liver fibrosis, and higher mortality in people with kidney disease.

What DCA Actually Is

Your liver makes primary bile acids from cholesterol and releases them into your intestine to help digest fat. Specific gut bacteria in your colon, including Clostridia and Ruminococcaceae, then chemically modify one of those primary acids (cholic acid) into DCA. A portion of that DCA gets reabsorbed and circulates through your bloodstream, where it can be measured.

DCA is not a protein, hormone, or enzyme. It is a small fat-derived molecule (a secondary bile acid) that doubles as a signaling molecule, activating receptors on your cells that influence immune function, metabolism, and how your gut barrier behaves.

Kidney Disease and Mortality Risk

This is where the evidence for DCA is strongest. In a study of 3,147 adults with chronic kidney disease stages 2 to 4 (CRIC Study), people with fasting DCA levels above the median had independently higher risks of end-stage kidney disease and death from any cause. The link held after adjusting for standard risk factors.

A separate study of 112 people with moderate to severe kidney disease found that those with serum DCA above 58 ng/mL had more buildup of calcium in their coronary arteries and lower bone mineral density at baseline. These associations held up even after accounting for the classic mineral markers doctors usually watch in kidney disease: calcium, phosphorus, vitamin D, PTH (parathyroid hormone), and FGF-23 (fibroblast growth factor 23).

What this means for you: if you already know you have kidney disease, a routine chemistry panel showing acceptable calcium and phosphorus does not rule out DCA-driven vascular and bone risk. DCA captures a different biological axis, one tied to your gut microbes rather than your mineral balance.

Liver Disease and Fibrosis

DCA tends to rise as fatty liver disease progresses. In adults with metabolic dysfunction-associated steatotic liver disease (MASLD, the current name for non-alcoholic fatty liver disease), higher bile acid levels, including DCA, track with advanced liver fibrosis. The pattern holds in children with MASLD as well.

A serum bile acid panel that included DCA distinguished chronic hepatitis B from cirrhosis with an area under the curve of 0.874, and chronic hepatitis B from liver cancer with an area under the curve of 0.825. Both beat the performance of ALT (alanine aminotransferase), AST (aspartate aminotransferase), and total bile acids alone. Area under the curve is a measure of how well a test separates two groups, where 1.0 is perfect and 0.5 is no better than a coin flip.

What this means for you: if your ALT and AST look normal but you have metabolic risk factors for fatty liver, DCA and related bile acids can pick up metabolic disruption that routine liver enzymes miss.

Heart Disease, Calcification, and a Counterintuitive Finding

In people with kidney disease, higher DCA tracks with more coronary artery calcification and worse long-term outcomes. But a separate cohort study of 1,730 people with established coronary artery disease found that higher serum levels of several unconjugated bile acids, including DCA, were associated with lower cardiovascular and all-cause mortality.

How do both findings fit together? DCA is not a simple "higher equals worse" number. It reflects a complex interplay between your gut bacteria, your liver's bile acid output, and whatever disease state your body is in. In failing kidneys, elevated DCA appears to drive vascular calcification. In people with intact liver and gut function, it may reflect a healthier microbiome producing more secondary bile acids. Context matters: your DCA level is more useful interpreted alongside your kidney function, liver health, and metabolic risk than read in isolation.

Gastric and Cancer-Related Changes

When bile refluxes into the stomach, DCA can activate a signaling cascade that promotes precancerous changes called gastric intestinal metaplasia. Research in people with these gastric changes found that elevated DCA in gastric juice was linked to this process through a pathway involving TGR5 (a bile acid receptor) and STAT3 (a signaling protein that drives cell growth and inflammation).

In colorectal cancer, a meta-analysis of fecal bile acid studies found higher fecal DCA concentrations associate with higher cancer risk. A prospective study of 1,093 people found higher serum bile acids were associated with increased colorectal cancer risk in women, though not in men.

Cognitive Decline and Brain Health

In a study of roughly 1,500 older adults, higher serum DCA and a higher DCA-to-cholic-acid ratio were associated with cognitive decline and Alzheimer's disease diagnosis. This reflects an altered gut-liver-brain axis and adds DCA to a growing list of blood-based signals linked to neurodegeneration, though its role remains exploratory.

Reference Ranges

DCA does not yet have universally standardized clinical cutpoints. Assay methods and populations vary, and different labs report different numbers. The ranges below come from the CKD literature, where DCA has been studied most rigorously, and should be interpreted as research-derived orientation rather than firm clinical targets.

These thresholds were derived in people with chronic kidney disease. They are not validated for healthy adults. Because DCA is measured by laboratory techniques that can shift meaningfully between labs, compare your own results within the same lab over time for the most meaningful trend.

Tracking Your Trend

A single DCA measurement has meaningful within-person variability. A reproducibility study in 136 people found that analytical precision of DCA testing was excellent (intraclass correlation coefficient above 0.83, where 1.0 would be perfect agreement between repeated measures). But reproducibility over 6 months was only moderate (intraclass correlation of 0.44 or higher), meaning real biological fluctuation from week to week and month to month is substantial.

The same researchers showed that averaging two or more samples taken over 6 months meaningfully improves the reliability of a person's "true" DCA level compared with relying on a single draw. Get a baseline, retest in 3 to 6 months if making dietary or medication changes, and at least annually thereafter. Standardize the conditions each time: same time of day, same fasting state, same recent diet, and ideally the same lab.

Decision Pathway for Abnormal Results

If your DCA comes back elevated, it is not a diagnosis. It is a signal that is worth interpreting against the rest of your metabolic picture. Consider pairing it with tests that cover the systems DCA is most likely reflecting: a comprehensive metabolic panel and cystatin C for kidney function, ALT, AST, and GGT (gamma-glutamyl transferase) for liver health, a lipid panel with ApoB (apolipoprotein B) for cardiovascular risk, and a stool test if you suspect gut dysbiosis.

Patterns worth investigating: elevated DCA plus reduced kidney filtration rate warrants a conversation with a nephrologist about vascular calcification risk. Elevated DCA plus rising ALT or AST or imaging evidence of fatty liver suggests involving a hepatologist and considering advanced fibrosis assessment. Elevated DCA with new cognitive symptoms is worth mentioning to a neurologist, though the evidence there is still early.

When Results Can Be Misleading

• Fasting status and meal timing: DCA varies with time of day and food intake. A non-fasting sample, or one drawn at a different time than your last, can shift results meaningfully. The CKD studies noted this as a limitation.
• Recent antibiotics: DCA is made by specific gut bacteria. A recent course of antibiotics can wipe out those bacteria and temporarily lower your DCA level without reflecting any change in your underlying disease risk. Wait at least 4 to 6 weeks after finishing antibiotics before testing.
• Active liver injury from medications: In drug-induced liver injury, DCA and related bile acids become markedly abnormal as part of global bile acid disruption. A study of 68 people with confirmed drug-induced liver injury found DCA changes did not differ much across causative drug classes, meaning any hepatotoxic drug can secondarily perturb DCA.
• Ursodeoxycholic acid therapy: This is a bile acid medication that modifies the entire bile acid pool and affects enterohepatic circulation. If you are taking it, DCA levels reflect treatment effects, not your baseline biology.

Where DCA Fits in the Bigger Picture

DCA is a newer, research-stage marker. It does not replace standard kidney, liver, or cardiovascular testing. But it captures information those tests cannot: the state of your gut microbiome's bile acid handling and its downstream effects on your arteries, bones, and liver. Getting a baseline now and tracking your trend gives you a head start, because you will have your own data to compare against as the science matures.